143 related articles for article (PubMed ID: 38219512)
1. Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: A case report.
Wang S; Wang Q; Jin L; Dong J; Ding J
Int J Surg Case Rep; 2024 Feb; 115():109241. PubMed ID: 38219512
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature.
Patelli G; Bencardino K; Tosi F; Pugliano M; Lanzani F; Innocenti A; Rinaldo A; Mauri G; Cerea G; Sartore-Bianchi A; Torre M; Agostoni EC; Siena S
J Med Case Rep; 2021 Feb; 15(1):32. PubMed ID: 33526108
[TBL] [Abstract][Full Text] [Related]
3. Exacerbation of Thymoma-Associated Myasthenia Gravis Following Efgartigimod Treatment Related to Anti-acetylcholine Receptor Antibody Overshoot: A Report of Two Cases.
Kawama K; Warabi Y; Bokuda K; Kimura H; Takahashi K
Cureus; 2023 Dec; 15(12):e50692. PubMed ID: 38229781
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
6. [Symptoms of myasthenia gravis in a patient with a history of thymectomy for invasive thymoma].
Giraldo LM; Duque C; Uribe CS; Hernández OH
Biomedica; 2015; 35(4):475-9. PubMed ID: 26844436
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis.
Xue L; Wang L; Dong J; Yuan Y; Fan H; Zhang Y; Wang Q; Ding J
Eur J Cardiothorac Surg; 2017 Oct; 52(4):692-697. PubMed ID: 29156018
[TBL] [Abstract][Full Text] [Related]
8. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
9. [Myasthenia gravis: perioperative complications of 1002 transsternal thymectomies - historical overwiev of 34 years long practice at one institution].
Kas J; Kocsis Á; Kiss D; Simon V; Komoly S; Rózsa C; Svastics E
Magy Seb; 2019 Sep; 72(3):83-97. PubMed ID: 31544487
[TBL] [Abstract][Full Text] [Related]
10. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Katyal N; Halldorsdottir K; Govindarajan R; Shieh P; Muley S; Reyes P; Leung KK; Mullen J; Milani-Nejad S; Korb M; Goyal NA; Mozaffar T; Goyal N; Habib AA; Muppidi S
Muscle Nerve; 2023 Nov; 68(5):762-766. PubMed ID: 37695277
[TBL] [Abstract][Full Text] [Related]
11. Eight-year follow-up of patients with myasthenia gravis after thymectomy.
Yu S; Li F; Chen B; Lin J; Yang M; Fu X; Li J; Bu B
Acta Neurol Scand; 2015 Feb; 131(2):94-101. PubMed ID: 25170783
[TBL] [Abstract][Full Text] [Related]
12. Thymoma complicated with myasthenia gravis and Good syndrome - a therapeutic conundrum: a case report.
Paranavitane S; Handagala S; De Silva R; Chang T
J Med Case Rep; 2019 Nov; 13(1):348. PubMed ID: 31779680
[TBL] [Abstract][Full Text] [Related]
13. [The efficacy of eculizumab against post-thymectomy exacerbations in thymoma associated myasthenia gravis (MG)].
Takeuchi E; Kajiyama Y; Ando K; Funaki S; Okuno T; Shintani Y; Mochizuki H
Rinsho Shinkeigaku; 2022 Apr; 62(4):277-280. PubMed ID: 35354724
[TBL] [Abstract][Full Text] [Related]
14. Clinical Comparative Analyses of Thymectomy Between Subxiphoid and Subcostal Arch Thoracoscopic Resection and Median Sternotomy for the Treatment of Thymoma With Myasthenia Gravis in Chinese Patients.
Yin X; Xue S; Wang H; Cheng S; Feng Z; Guo Y; Zhou Y; Zhao Z
J Surg Res; 2023 May; 285():107-113. PubMed ID: 36652769
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic strategy in myasthenia gravis].
Tranchant C
Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
[TBL] [Abstract][Full Text] [Related]
16. Efgartigimod in refractory autoimmune myasthenia gravis.
Remijn-Nelissen L; Tannemaat MR; Ruiter AM; Campman YJM; Verschuuren JJGM
Muscle Nerve; 2024 Jun; ():. PubMed ID: 38899431
[TBL] [Abstract][Full Text] [Related]
17. Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy.
Tsukaguchi M; Shimamura M; Ikeda K; Urai Y; Sasaki I; Deguchi K; Touge T; Takeuchi H; Kuriyama S
J Neurol Sci; 2005 Apr; 231(1-2):85-8. PubMed ID: 15792826
[TBL] [Abstract][Full Text] [Related]
18. Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report.
Zhang Z; Yang M; Luo T; Du X; Wang Z; Huang X; Zhang Y
Ther Adv Neurol Disord; 2024; 17():17562864241254895. PubMed ID: 38813520
[TBL] [Abstract][Full Text] [Related]
19. Plasmaexchange in the treatment of myasthenia gravis associated with thymoma.
Gogovska L; Ljapcev R; Polenakovic M; Stojkovski L; Popovska M; Grcevska L
Int J Artif Organs; 2003 Feb; 26(2):170-3. PubMed ID: 12653352
[TBL] [Abstract][Full Text] [Related]
20. Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.
Dos Santos JBR; Gomes RM; da Silva MRR
Expert Rev Clin Immunol; 2022 Sep; 18(9):879-888. PubMed ID: 35892247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
